期刊
NATURE MEDICINE
卷 17, 期 10, 页码 1228-1230出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.2435
关键词
-
资金
- Istituto San Paolo di Torino and Regione Piemonte (Turin, Italy)
- Volkswagen Foundation (Hannover, Germany)
Placebo analgesia is mediated by both opioid and nonopioid mechanisms, but so far nothing is known about the nonopioid component. Here we show that the specific CB1 cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-1-pyrazole-3-carboxamide (rimonabant or SR141716) blocks nonopioid placebo analgesic responses but has no effect on opioid placebo responses. These findings suggest that the endocannabinoid system has a pivotal role in placebo analgesia in some circumstances when the opioid system is not involved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据